Saudi Arabia Guidelines for diabetic macular edema

References

1. 1.↵
   1. Kaiser AB,
   2. Zhang N,
   3. Der Pluijm W VAN.

   Global prevalence of type 2 diabetes over the next ten years (2018-2028). Diabetes 2018; 67 (Supplement 1): 202-LB.
2. 2.↵
   International Diabetes Federation. IDF Diabetic Atlas 7th Edition. Int Diabetes Fed 2015; 39: 1–144.

   OpenUrl
3. 3.↵
   World Health Organization. Diabetes Key Fact [ Updated 2020 June 8. Cited 2020 November 20] Available from URL: https://www.who.int/news-room/fact-sheets/detail/diabetes
4. 4.↵
   1. Chawla A,
   2. Chawla R,
   3. Jaggi S.

   Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab 2016; 20: 546–551.

   OpenUrlCrossRefPubMed
5. 5.
   1. Kalofoutis C,
   2. Piperi C,
   3. Kalofoutis A,
   4. Harris F,
   5. Phoenix D,
   6. Singh J.

   Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol 2007; 12: 17–28.

   OpenUrlPubMed
6. 6.↵
   1. Orasanu G,
   2. Plutzky J.

   The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53: S35–S42.

   OpenUrlFREE Full Text
7. 7.↵
   1. Klein R,
   2. Knudtson MD,
   3. Lee KE,
   4. Gangnon R,
   5. Klein BEK.

   The Wisconsin epidemiologic study of diabetic retinopathy XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes Ophthalmology 2008; 115: 1859–1868.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Zhang X,
   2. Zeng H,
   3. Bao S,
   4. Wang N,
   5. Gillies MC.

   Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014; 4: 27.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kempen JH,
   2. O’Colmain BJ,
   3. Leske MC,
   4. Haffner SM,
   5. Klein R,
   6. Moss SE, et al.

   The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–563.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. White NH,
    2. Sun W,
    3. Cleary PA,
    4. Tamborlane W V,
    5. Danis RP,
    6. Hainsworth DP, et al.

    Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59: 1244–1253.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Bhagat N,
    2. Grigorian RA,
    3. Tutela A,
    4. Zarbin MA.

    Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1–32.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Zhang X,
    2. Bao S,
    3. Lai D,
    4. Rapkins RW,
    5. Gillies MC.

    Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of vegf-a and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026–1033.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Leal EC,
    2. Manivannan A,
    3. Hosoya KI,
    4. Terasaki T,
    5. Cunha-Vaz J,
    6. Ambro´sio AF, et al.

    Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Investig Opthalmology Vis Sci 2007; 48: 5257.

    OpenUrl
14. 14.↵
    1. Gundogan FC,
    2. Yolcu U,
    3. Akay F,
    4. Ilhan A,
    5. Ozge G,
    6. Uzun S.

    Diabetic macular edema: a short review. Pakistan J Med Sci 1969; 32: 505–510.

    OpenUrl
15. 15.↵
    1. Gundogan FC,
    2. Yolcu U,
    3. Akay F,
    4. Ilhan A,
    5. Ozge G,
    6. Uzun S.

    Diabetic macular edema. Pak J Med Sci 2016; 32: 505–510.

    OpenUrl
16. 16.↵
    1. Varley MP,
    2. Frank E,
    3. Purnell EW.

    Subretinal neovascularization after focal argon laser for diabetic macular edema. Ophthalmology 1988; 95: 567–573.

    OpenUrlPubMedWeb of Science
17. 17.↵
    1. Guyer DR,
    2. D’Amico DJ,
    3. Smith CW.

    Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 652–656.

    OpenUrlPubMedWeb of Science
18. 18.↵
    1. Alkhamis A.

    Health care system in Saudi Arabia: An overview. East Mediterr Heal J 2012; 18: 1078–1079.

    OpenUrl
19. 19.↵
    1. Al-Rubeaan K,
    2. Abu El-Asrar AM,
    3. Youssef AM,
    4. Subhani SN,
    5. Ahmad NA,
    6. Al-Sharqawi AH, et al.

    Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: A Saudi National Diabetes Registry-based study. Acta Ophthalmol 2015; 93: E140–E147.

    OpenUrl
20. 20.↵
    1. Singh PR

    1. Modi YS,
    2. Pecen PE,
    3. Schachat AP.

    Management of diabetic macular edema. In: Singh PR, editor. Managing Diabetic Eye Disease in Clinical Practice. Switzerland (AG); Springer International Publishing: 2015. p. 81–103.
21. 21.↵
    Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report no. 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985; 103: 1796–1806.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Iaccarino G,
    2. Ciccarelli M,
    3. Sorriento D,
    4. Galasso G,
    5. Campanile A,
    6. Santulli G

    , et al.Ischemic neoangiogenesis enhanced by β2 - adrenergic receptor overexpression. A novel role for the endothelial adrenergic system. Circ Res 2005; 97: 1182–119.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Williams KP,
    2. Steinle JJ.

    Maintenance of beta-adrenergic receptor signaling can reduce fas signaling in human retinal endothelial cells. Exp Eye Res 2009; 89: 448–455.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Melder RJ,
    2. Koenig GC,
    3. Witwer BP,
    4. Safabakhsh N,
    5. Munn LL,
    6. Jain RK.

    During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992–997.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Park HYL,
    2. Kim JH,
    3. Park CK.

    Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol 2014; 184: 1752–1762.

    OpenUrlCrossRefPubMed
26. 26.↵
    The Royal College of Ophthalmologists. Clinical Guidelines for Diabetic Retinopathy: A Summary. [Updated 2012. Cited 2021 January 9]; Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013.pdf
27. 27.↵
    1. Romero-Aroca P,
    2. Baget-Bernaldiz M,
    3. Pareja-Rios A,
    4. Lopez-Galvez M,
    5. Navarro-Gil R,
    6. Verges R.

    Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273.

    OpenUrl
28. 28.↵
    1. Chung YR,
    2. Kim YH,
    3. Ha SJ,
    4. Byeon HE,
    5. Cho CH,
    6. Kim JH, et al.

    Role of inflammation in classification of diabetic macular edema by optical coherence tomography. J Diabetes Res 2019; 2019: 8164250.

    OpenUrl
29. 29.↵
    1. Noma H,
    2. Mimura T,
    3. Yasuda K,
    4. Shimura M.

    Role of inflammation in diabetic macular edema. Ophthalmologica 2014; 232: 127–135.

    OpenUrl
30. 30.↵
    1. Yau JWY,
    2. Rogers SL,
    3. Kawasaki R,
    4. Lamoureux EL,
    5. Kowalski JW,
    6. Bek T, et al.

    Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556–564.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Lee R,
    2. Wong TY,
    3. Sabanayagam C.

    Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis 2015; 2: 17.

    OpenUrlPubMed
32. 32.↵
    1. Paulus YM,
    2. Gariano RF.

    Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009; 64: 16–20.

    OpenUrlPubMed
33. 33.↵
    1. Varma R,
    2. Bressler NM,
    3. Doan Q V,
    4. Gleeson M,
    5. Danese M,
    6. Bower JK, et al.

    Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014; 132: 1334–1340.

    OpenUrl
34. 34.↵
    1. Li JQ,
    2. Welchowski T,
    3. Schmid M,
    4. Letow J,
    5. Wolpers C,
    6. Pascual-Camps I, et al.

    Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol 2019; 35: 11–23.

    OpenUrl
35. 35.↵
    1. Wong TY,
    2. Cheung N,
    3. Tay WT,
    4. Wang JJ,
    5. Aung T,
    6. Saw SM, et al.

    Prevalence and risk factors for diabetic retinopathy. Ophthalmology 2008; 115: 1869–1875.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Dehghan MH,
    2. Katibeh M,
    3. Ahmadieh H,
    4. Nourinia R,
    5. Yaseri M.

    Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: The Yazd eye study. J Diabetes 2015; 7: 139–141.

    OpenUrl
37. 37.
    1. Pedro RA,
    2. Ramon SA,
    3. Marc BB,
    4. Juan FB,
    5. Isabel MM.

    Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the north-east of Spain, a population-based study. Ophthalmic Epidemiol 2010; 17: 251–265.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Knudsen LL,
    2. Lervang H-H,
    3. Lundbye-Christensen S,
    4. Gorst-Rasmussen A.

    The North Jutland County Diabetic Retinopathy Study: population characteristics. Br J Ophthalmol 2006; 90: 1404–1409.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Kahloun R,
    2. Jelliti B,
    3. Zaouali S,
    4. Attia S,
    5. Ben Yahia S,
    6. Resnikoff S, et al.

    Prevalence and causes of visual impairment in diabetic patients in Tunisia, North Africa. Eye 2014; 28: 986–991.

    OpenUrl
40. 40.↵
    1. MacKy TA,
    2. Khater N,
    3. Al-Zamil MA,
    4. El Fishawy H,
    5. Soliman MM.

    Epidemiology of diabetic retinopathy in Egypt: A hospital-based study. Ophthalmic Res 2011; 45: 73–78.

    OpenUrlPubMed
41. 41.↵
    1. Al Ghamdi AH,
    2. Rabiu M,
    3. Hajar S,
    4. Yorston D,
    5. Kuper H,
    6. Polack S.

    Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia. Br J Ophthalmol 2012; 96: 1168–1172.

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. El-Bab MF,
    2. Shawki N,
    3. AL-Sisi A,
    4. Akhtar M.

    Retinopathy and risk factors in diabetic patients from Al-Madinah Al-Munawarah in the Kingdom of Saudi Arabia. Clin Ophthalmol 2012; 6: 269–276.

    OpenUrlPubMed
43. 43.↵
    1. Hajar S,
    2. Al Hazmi A,
    3. Wasli M,
    4. Mousa A,
    5. Rabiu M.

    Prevalence and causes of blindness and diabetic retinopathy in Southern Saudi Arabia. Saudi Med J 2015; 36: 449–455.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Khan A,
    2. Wiseberg J,
    3. Lateef ZA,
    4. Khan S.

    Prevalence and determinants of diabetic retinopathy in Al Hasa region of Saudi Arabia: primary health care centre based cross-sectional survey, 2007-2009. Middle East Afr J Ophthalmol 2010; 17: 257–263.

    OpenUrlPubMed
45. 45.↵
    1. Alshaya AK,
    2. Alsayegh AK,
    3. Alshaya HK,
    4. Almutlaq BA,
    5. Alenazi NSG,
    6. Rasheedi HMA Al, et al.

    The common complications and comorbidities among Saudi diabetic patients in Northern Saudi Arabia. Open J Endocr Metab Dis 2017; 07: 151–161.

    OpenUrl
46. 46.↵
    1. Pelzek C,
    2. Lim JI.

    Diabetic macular edema: Review and update. Ophthalmol Clin North Am 2002; 15: 555–563.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Misra GP,
    2. Imai H,
    3. Singh RJ,
    4. Lowe TL,
    5. Gardner TW.

    Diabetic retinopathy and diabetic macular edema. Retinal Pharmacotherapy 2010; 2010: 133–136.

    OpenUrl
48. 48.↵
    1. Bandello F,
    2. Pognuz R,
    3. Polito A,
    4. Pirracchio A,
    5. Menchini F,
    6. Ambesi M.

    Diabetic macular edema: classification, medical and laser therapy. Semin Ophthalmol 2003; 18: 251–258.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Salz DA,
    2. Witkin AJ.

    Imaging in diabetic retinopathy. Middle East Afr J Ophthalmol 2015; 22: 145–150.

    OpenUrl
50. 50.↵
    1. Sikorski BL,
    2. Malukiewicz G,
    3. Stafiej J,
    4. Lesiewska-Junk H,
    5. Raczynska D.

    The diagnostic function of OCT in diabetic maculopathy. Mediators Inflamm 2013; 2013: 434560.

    OpenUrl
51. 51.↵
    1. Kim BY,
    2. Smith SD,
    3. Kaiser PK.

    Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 2006; 142: 405–412.

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Zur D,
    2. Iglicki M,
    3. Busch C,
    4. Invernizzi A,
    5. Mariussi M,
    6. Loewenstein A, et al.

    OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 2018; 125: 267–275.

    OpenUrl
53. 53.↵
    1. Baskin DE.

    Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol 2010; 21: 172–177.

    OpenUrlCrossRefPubMed
54. 54.↵
    1. Bhende M,
    2. Shetty S,
    3. Parthasarathy M,
    4. Ramya S.

    Optical coherence tomography: A guide to interpretation of common macular diseases. Indian J Ophthalmol 2018; 66: 20–35.

    OpenUrl
55. 55.↵
    1. Lee J,
    2. Moon BG,
    3. Cho AR,
    4. Yoon YH.

    Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology 2016; 123: 2368–2375.

    OpenUrlPubMed
56. 56.↵
    1. Hsieh YT,
    2. Alam MN,
    3. Le D,
    4. Hsiao CC,
    5. Yang CH,
    6. Chao DL, et al.

    OCT Angiography Biomarkers for predicting visual outcomes after ranibizumab treatment for diabetic macular edema. Ophthalmology Retina 2019; 3: 826–834.

    OpenUrl
57. 57.↵
    1. Kwan CC,
    2. Fawzi AA.

    Imaging and biomarkers in diabetic macular edema and diabetic retinopathy. Curr Diab Rep 2019; 19: 95.

    OpenUrl
58. 58.↵
    1. Kiire CA,
    2. Porta M,
    3. Chong V.

    Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol 2013 ; 58: 459–465.

    OpenUrlCrossRefPubMed
59. 59.↵
    1. Romero-Aroca P,
    2. Reyes-Torres J,
    3. Baget-Bernaldiz M,
    4. Blasco-Sune C.

    Laser treatment for diabetic macular edema in the 21st Century. Curr Diabetes Rev 2014; 10: 100–112.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Scholz P,
    2. Altay L,
    3. Fauser S.

    A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 2017; 34: 1528–1555.

    OpenUrl
61. 61.↵
    Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 1987; 94: 761–774.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    1. Reddy SV,
    2. Husain D.

    Panretinal photocoagulation: a review of complications. Semin Ophthalmol 2018; 33: 83–88.

    OpenUrl
64. 64.↵
    1. Dorin G.

    Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol 2004; 19: 62–68.

    OpenUrlCrossRefPubMed
65. 65.↵
    1. Mitchell P,
    2. Bandello F,
    3. Schmidt-Erfurth U,
    4. Lang GE,
    5. Massin P,
    6. Schlingemann RO, et al.

    The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–625.

    OpenUrlCrossRefPubMedWeb of Science
66. 66.
    1. Elman MJ,
    2. Aiello LP,
    3. Beck RW,
    4. Bressler NM,
    5. Bressler SB,
    6. Edwards AR, et al.

    Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–1077.

    OpenUrlCrossRefPubMedWeb of Science
67. 67.↵
    1. Michaelides M,
    2. Kaines A,
    3. Hamilton RD,
    4. Fraser-Bell S,
    5. Rajendram R,
    6. Quhill F, et al.

    A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study). 12-month data: Report 2. Ophthalmology 2010; 117: 1078–1086.

    OpenUrlCrossRefPubMedWeb of Science
68. 68.↵
    1. Browning DJ,
    2. Stewart MW,
    3. Lee C.

    Diabetic macular edema: Evidence-based management. Indian J Ophthalmol 2018; 66: 1736–1750.

    OpenUrl
69. 69.↵
    1. Neubauer AS,
    2. Ulbig MW.

    Laser treatment in diabetic retinopathy. Ophthalmologica 2007; 221: 95–102.

    OpenUrlCrossRefPubMed
70. 70.↵
    1. Gross J.

    DRCR.net Prompt PRP vs ranibizumab+deferred PRP for PDR study (Protocol S). Presented at: American Academy of Ophthalmology. Nov. 13, 2015; Las Vegas.
71. 71.↵
    1. Heier JS,
    2. Bressler NM,
    3. Avery RL,
    4. Bakri SJ,
    5. Boyer DS,
    6. Brown DM, et al.

    Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema. JAMA Ophthalmol 2016; 134: 95–99.

    OpenUrl
72. 72.↵
    1. Su L,
    2. Ren X,
    3. Wei H,
    4. Zhao L,
    5. Zhang X,
    6. Liu J, et al.

    Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina 2016; 36: 938–943.

    OpenUrl
73. 73.↵
    1. Nguyen QD,
    2. Brown DM,
    3. Marcus DM,
    4. Boyer DS,
    5. Patel S,
    6. Feiner L, et al.

    Ranibizumab for diabetic macular edema. Ophthalmology 2012; 119: 789–801.

    OpenUrlCrossRefPubMedWeb of Science
74. 74.↵
    1. Schmidt-Erfurth U,
    2. Lang GE,
    3. Holz FG,
    4. Schlingemann RO,
    5. Lanzetta P,
    6. Massin P, et al.

    Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema. Ophthalmology 2014; 125: 1045–1053.

    OpenUrl
75. 75.↵
    1. Das T,
    2. Aurora A,
    3. Chhablani J,
    4. Giridhar A,
    5. Kumar A,
    6. Raman R, et al.

    Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol 2016; 64: 14–25.

    OpenUrl
76. 76.↵
    1. Saishin Y,
    2. Saishin Y,
    3. Takahashi K,
    4. Silva RLE,
    5. Hylton D,
    6. Rudge JS, et al.

    VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195: 241–248.

    OpenUrlCrossRefPubMedWeb of Science
77. 77.↵
    1. Korobelnik JF,
    2. Do DV,
    3. Schmidt-Erfurth U,
    4. Boyer DS,
    5. Holz FG,
    6. Heier JS, et al.

    Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247–2254.

    OpenUrlCrossRefPubMed
78. 78.↵
    1. Chen YP,
    2. Wu AL,
    3. Chuang CC,
    4. Chen SN.

    Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep 2019; 9: 10952.

    OpenUrl
79. 79.↵
    1. Epstein D,
    2. Mirabelli P,
    3. Lövestam Adrian M.

    Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema. Acta Ophthalmol 2020; 98: e258–e529.

    OpenUrl
80. 80.↵
    1. Elman MJ,
    2. Qin H,
    3. Aiello LP,
    4. Beck RW,
    5. Bressler NM,
    6. Ferris FL, et al.

    Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results. Ophthalmology 2012; 119: 2312–2318.

    OpenUrlCrossRefPubMedWeb of Science
81. 81.↵
    1. Michaelides M,
    2. Kaines A,
    3. Hamilton RDR,
    4. Fraser-Bell S,
    5. Rajendram R,
    6. Quhill F, et al.

    A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT 2) in the management of diabetic macular edema. Arch Ophthalmol 2012; 130: 972–979.

    OpenUrlCrossRefPubMed
82. 82.↵
    1. Schmidt-Erfurth U,
    2. Garcia-Arumi J,
    3. Bandello F,
    4. Berg K,
    5. Chakravarthy U,
    6. Gerendas BS, et al.

    Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237: 185–222.

    OpenUrlPubMed
83. 83.↵
    1. Zhang Y,
    2. Ma J,
    3. Meng N,
    4. Li H,
    5. Qu Y.

    Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: a meta-analysis. Curr Eye Res 2013; 38: 578–587.

    OpenUrlCrossRefPubMed
84. 84.
    1. Yolcu Ü,
    2. Sobaci G.

    The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections. Int Ophthalmol 2015; 35: 73–79.

    OpenUrl
85. 85.↵
    1. Durukan AH,
    2. Memisoglu S,
    3. Gundogan FC.

    Is multifocal ERG a reliable index of macular function after triamcinolone acetonide injection in diffuse diabetic macular edema? Eur J Ophthalmol 2009; 19: 1017–1027.

    OpenUrlPubMed
86. 86.↵
    1. Elman MJ,
    2. Bressler NM,
    3. Qin H,
    4. Beck RW,
    5. Ferris FL,
    6. Friedman SM, et al.

    Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609–614.

    OpenUrlCrossRefPubMedWeb of Science
87. 87.↵
    1. Gillies MC,
    2. Sutter FKP,
    3. Simpson JM,
    4. Larsson J,
    5. Ali H,
    6. Zhu M.

    Intravitreal triamcinolone for refractory diabetic macular edema. Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538.

    OpenUrlCrossRefPubMedWeb of Science
88. 88.↵
    1. Qi HP,
    2. Bi S,
    3. Wei SQ,
    4. Cui H,
    5. Zhao JB.

    Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res 2012; 37: 1136–1147.

    OpenUrlPubMed
89. 89.↵
    1. Schwartz SG,
    2. Scott IU,
    3. Stewart MW,
    4. Flynn HW.

    Update on corticosteroids for diabetic macular edema. Clinical Ophthalmology 2016; 10: 1723–1730.

    OpenUrl
90. 90.↵
    1. Cabrera M,
    2. Yeh S,
    3. Albini TA.

    Sustained-release corticosteroid options. J Ophthalmol 2014; 2014: 1–5.

    OpenUrlPubMed
91. 91.
    1. Bahrami B,
    2. Hong T,
    3. Zhu M,
    4. Schlub TE,
    5. Chang A.

    Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefe’s Arch Clin Exp Ophthalmol 2017; 255: 1133–1140.

    OpenUrl
92. 92.
    1. Kaiho T,
    2. Oshitari T,
    3. Tatsumi T,
    4. Takatsuna Y,
    5. Arai M,
    6. Shimizu N, et al.

    Efficacy of one-year treatment with aflibercept for diabetic macular edema with practical protocol. Biomed Res Int 2017; 2017: 1–6.

    OpenUrl
93. 93.
    1. Aksoy S,
    2. Yilmaz G,
    3. Akkoyun I,
    4. Yazici AC.

    Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema. Int J Ophthalmol 2015; 8: 550–555.

    OpenUrl
94. 94.
    1. Fong DS,
    2. Luong TQ,
    3. Contreras R,
    4. Jimenez JJ,
    5. Custis PH,
    6. Patel V, et al.

    Treatment patterns and 2-year vision outcomes with bevacizumab in diabetic macular edema an analysis from a large U.S. Integrated health care system. Retina 2018; 38: 1830–1838.

    OpenUrl
95. 95.
    1. Güler E,
    2. Totan Y,
    3. Betül Güragaç F.

    Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema. Cutan Ocul Toxicol 2017; 36: 180–184.

    OpenUrl
96. 96.
    1. Koç I,
    2. Kadaylfçllar S,
    3. Eldem B.

    Real-world results of intravitreal ranibizumab, bevacizumab, or triamcinolone for diabetic macular edema. Ophthalmologica 2018; 239: 85–93.

    OpenUrl
97. 97.
    1. Riazi-Esfahani M,
    2. Riazi-Esfahani H,
    3. Ahmadraji A,
    4. Karkhaneh R,
    5. Mahmoudi A,
    6. Roohipoor R, et al.

    Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. Int Ophthalmol 2018; 38: 585–598.

    OpenUrl
98. 98.
    1. Cheema HR,
    2. Al Habash A,
    3. Al-Askar E.

    Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema. Int J Ophthalmol 2014; 7: 251–255.

    OpenUrl
99. 99.
    1. Ciulla TA,
    2. Hussain RM,
    3. Ciulla LM,
    4. Sink B,
    5. Harris A.

    Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina 2016; 36: 1292–1297.

    OpenUrl
100. 100.
     1. Egan C,
     2. Zhu H,
     3. Lee A,
     4. Sim D,
     5. Mitry D,
     6. Bailey C, et al.

     The United Kingdom Diabetic retinopathy electronic medical record users group, report 1: Baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol 2017; 101: 75–80.

     OpenUrlAbstract/FREE Full Text
101. 101.↵
     1. Fassbender Adeniran JM,
     2. Jusufbegovic D,
     3. Schaal S.

     Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm 2017; 25: 834–840.

     OpenUrl
102. 102.↵
     1. Boyer DS,
     2. Yoon YH,
     3. Belfort R,
     4. Bandello F,
     5. Maturi RK,
     6. Augustin AJ, et al.

     Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904–1914.

     OpenUrlCrossRefPubMed
103. 103.↵
     1. Callanan DG,
     2. Gupta S,
     3. Boyer DS,
     4. Ciulla TA,
     5. Singer MA,
     6. Kuppermann BD, et al.

     Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843–1851.

     OpenUrlCrossRefPubMed
104. 104.↵
     1. Cebeci Z,
     2. Kir N.

     Role of implants in the treatment of diabetic macular edema: Focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes 2015; 8: 555–566.

     OpenUrl
105. 105.↵
     1. Murakami T,
     2. Yoshimura N.

     Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res 2013; 2013: 920713.

     OpenUrl
106. 106.↵
     1. Dugel PU,
     2. Campbell JH,
     3. Kiss S,
     4. Loewenstein A,
     5. Shih V,
     6. Xu X, et al.

     Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina 2019; 39: 88–97.

     OpenUrlPubMed
107. 107.↵
     1. Gonzalez VH,
     2. Campbell J,
     3. Holekamp NM,
     4. Kiss S,
     5. Loewenstein A,
     6. Augustin AJ, et al.

     Early and long-term responses to anti–vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 2016; 172: 72–79.

     OpenUrlPubMed
108. 108.↵
     1. Cicinelli MV,
     2. Cavalleri M,
     3. Querques L,
     4. Rabiolo A,
     5. Bandello F,
     6. Querques G.

     Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol 2017; 101: 1689–1693.

     OpenUrlAbstract/FREE Full Text
109. 109.↵
     1. Busch C,
     2. Zur D,
     3. Fraser-Bell S,
     4. Laíns I,
     5. Santos AR,
     6. Lupidi M, et al.

     Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 2018; 55: 789–796.

     OpenUrlPubMed
110. 110.
     1. Chatziralli I,
     2. Theodossiadis P,
     3. Parikakis E,
     4. Dimitriou E,
     5. Xirou T,
     6. Theodossiadis G, et al.

     Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 2017; 8: 1393–1404.

     OpenUrl
111. 111.
     1. Iglicki M,
     2. Busch C,
     3. Zur D,
     4. Okada M,
     5. Mariussi M,
     6. Chhablani JK, et al.

     Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The international retina group real-life 24-month multicenter study: The irgrel-dex study. Retina 2019; 39: 44–51.

     OpenUrl
112. 112.
     1. Guigou S,
     2. Pommier S,
     3. Meyer F,
     4. Hajjar C,
     5. Merite PY,
     6. Parrat E, et al.

     Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica 2015; 233: 169–175.

     OpenUrl
113. 113.
     1. Pareja-Ríos A,
     2. Ruiz-De la Fuente-Rodríguez P,
     3. Bonaque-González S,
     4. López-Gálvez M,
     5. Lozano-López V,
     6. Romero-Aroca P.

     Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmo 2018; 11: 77–82.

     OpenUrl
114. 114.
     1. Bellocq D,
     2. Akesbi J,
     3. Matonti F,
     4. Vartin C,
     5. Despreaux R,
     6. Comet A, et al.

     The pattern of recurrence in diabetic macular edema treated by dexamethasone implant: The PREDIAMEX study. Ophthalmol Retin 2018; 2: 567–573.

     OpenUrl
115. 115.↵
     1. Malcles A,
     2. Dot C,
     3. Voirin N,
     4. Agard E,
     5. Vie AL,
     6. Bellocq D, et al.

     Real-life study in diabetic macular edema treated with dexamethasone implant: The reldex study. Retina 2017; 37: 753–760.

     OpenUrl
116. 116.
     1. Scaramuzzi M,
     2. Querques G,
     3. Spina C La,
     4. Lattanzio R,
     5. Bandello F.

     Repeated intravitreal dexamethasone implant (ozurdex) for diabetic macular EDEMA. Retina 2015; 35: 1216–1222.

     OpenUrlCrossRefPubMed
117. 117.↵
     1. Ozsaygili C,
     2. Duru N.

     Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment. Retina 2020; 40: 1044–1052.

     OpenUrl
118. 118.↵
     1. Augsburger M,
     2. Sarra GM,
     3. Imesch P.

     Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefe’s Arch Clin Exp Ophthalmol 2019; 257: 1889–1895.

     OpenUrl
119. 119.↵
     1. Rosenthal JM,
     2. Johnson MW.

     Management of retinal diseases in pregnant patients. J Ophthalmic Vis Res 2018; 13: 62–65.

     OpenUrl
120. 120.↵
     1. Baker CW,
     2. Glassman AR,
     3. Beaulieu WT,
     4. Antoszyk AN,
     5. Browning DJ,
     6. Chalam K V, et al.

     Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA 2019; 321: 1880–1894.

     OpenUrl
121. 121.↵
     1. Regillo CD,
     2. Callanan DG,
     3. Do D V.,
     4. Fine HF,
     5. Holekamp NM,
     6. Kuppermann BD, et al.

     Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel. Ophthalmic Surg Lasers Imaging Retina 2017; 48: 291–301.

     OpenUrl
122. 122.↵
     1. García Layana A,
     2. Adán A,
     3. Ascaso FJ,
     4. Cabrera F,
     5. Donate J,
     6. Escobar Barranco JJ, et al.

     Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach. Eur J Ophthalmol 2020; 30: 1042–1052.

     OpenUrl
123. 123.↵
     1. Giovannini A,
     2. Parravano M,
     3. Ricci F,
     4. Bandello F.

     Management of diabetic macular edema with intravitreal dexamethasone implants: expert recommendations using a Delphi-based approach. Eur J Ophthalmol 2019; 29: 82–91.

     OpenUrl
124. 124.↵
     1. Kodjikian L,
     2. Bellocq D,
     3. Bandello F,
     4. Loewenstein A,
     5. Chakravarthy U,
     6. Koh A, et al.

     First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol 2019; 29: 573–584.

     OpenUrl
125. 125.↵
     1. Bandello F,
     2. Cicinelli M,
     3. Parodi M.

     Anti-VEGF molecules for the management of diabetic macular edema. Curr Pharm Des 2015; 210: 4731–4737.

     OpenUrl
126. 126.↵
     1. Vujosevic S,
     2. Torresin T,
     3. Berton M,
     4. Bini S,
     5. Convento E,
     6. Midena E.

     Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol 2017; 181: 149–155.

     OpenUrl
127. 127.↵
     1. Elman MJ,
     2. Sloan MD,
     3. Starr JA,
     4. Butcher TM,
     5. Singletary P V,
     6. Gore N, et al.

     Observational study of subclinical diabetic macular edema. Eye (Lond) 2012; 26: 833–840.

     OpenUrl
128. 128.↵
     1. Boyle J,
     2. Vukicevic M,
     3. Koklanis K,
     4. Itsiopoulos C,
     5. Rees G.

     Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Heal Med 2018; 23: 127–140.

     OpenUrl
129. 129.↵
     1. Ramu J,
     2. Chatziralli I,
     3. Yang Y,
     4. Menon G,
     5. Bailey C,
     6. Eckstein M, et al.

     Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Prefer Adherence 2017; 11: 579–586.

     OpenUrl
130. 130.↵
     1. Patel AJ,
     2. Downes K,
     3. Davis A,
     4. Das A.

     Are proliferative diabetic retinopathy and diabetic macular edema two different disease processes? A retrospective cross-sectional. Investig Ophthalmol Vis Sci 2012; 53: 377.

     OpenUrl